Amifampridine is indicated for:
Irrespective of gender only Adults (18 years old or older)
Symptomatic treatment of Lambert-Eaton myasthenic syndrome (LEMS) in adults.
For this indication, the medical literature mentions below treatments (click for details):
Active ingredient Amifampridine is contraindicated in the following cases:
Based on the pharmacodynamic properties of amifampridine, the concomitant use with medicinal products known to cause QT prolongation (e.g., disopyramide, cisapride, domperidone, rifampicin and ketoconazole) is contraindicated as this combination may lead to an enhanced risk of ventricular tachycardia, notably torsade de pointes.
Concomitant use with sultopride.
In patients with congenital QT syndromes.